Preclinical efficacy profiles of the sigma‐1 modulator E1R and of fenfluramine in two chronic mouse epilepsy models

Abstract

AbstractObjectiveGiven its key homeostatic role affecting mitochondria, ionotropic and metabotropic receptors, and voltage‐gated ion channels, sigma‐1 receptor (Sig1R) represents an interesting target for epilepsy management. Antiseizure effects of the positive allosteric modulator E1R have already been reported in acute seizure models. Although modulation of serotonergic neurotransmission is considered the main mechanism of action of fenfluramine, its interaction with Sig1R may be of additional relevance.MethodsTo further explore the potential of Sig1R as a target, we assessed the efficacy and tolerability of E1R and fenfluramine in two chronic mouse models, including an amygdala kindling paradigm and the intrahippocampal kainate model. The relative contribution of the interaction with Sig1R was analyzed using combination experiments with the Sig1R antagonist NE‐100.ResultsWhereas E1R exerted pronounced dose‐dependent antiseizure effects at well‐tolerated doses in fully kindled mice, only limited effects were observed in response to fenfluramine, without a clear dose dependency. In the intrahippocampal kainate model, E1R failed to influence electrographic seizure activity. In contrast, fenfluramine significantly reduced the frequency of electrographic seizure events and their cumulative duration. Pretreatment with NE‐100 reduced the effects of E1R and fenfluramine in the kindling model. Surprisingly, pre‐exposure to NE‐100 in the intrahippocampal kainate model rather enhanced and prolonged fenfluramine's antiseizure effects.SignificanceIn conclusion, the kindling data further support Sig1R as an interesting target for novel antiseizure medications. However, it is necessary to further explore the preclinical profile of E1R in chronic epilepsy models with spontaneous seizures. Despite the rather limited effects in the kindling paradigm, the findings from the intrahippocampal kainate model suggest that it is of interest to further assess a possible broad‐spectrum potential of fenfluramine.